Biomatter develops proteins and enzymes with Intelligent Architecture™ for health and sustainable manufacturing. The company provides solutions from initial concept to protein production.

Biomatter

Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. Through its discovery of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. With a distinguished team including co-founder and CRISPR-Cas genome editing co-inventor Jennifer Doudna, Mammoth is addressing challenges across healthcare, agriculture, environmental monitoring, biodefense, and more.

Janice Chen

Trevor Martin

Jennifer Doudna

Ashley Tehranchi

Lucas Harrington

Mammoth Biosciences

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

Amyris, Inc.

Atomwise is a preclinical pharma company revolutionizing drug discovery with AI. They have invented the use of deep learning for structure-based drug discovery and are developing a pipeline of small-molecule drug candidates. Their AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. Atomwise is tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies.

Izhar Wallach

Alexander Levy

Abraham Heifets

Atomwise

Biomatter | 4,464 followers on LinkedIn. Creating proteins with Intelligent Architecture™ for health and sustainable manufacturing | Biomatter (previously called Biomatter Designs) is a synthetic biology company that creates new proteins for health and sustainable manufacturing applications. The company has developed the Intelligent Architecture™ platform that addresses limitations of current engineering approaches to unlock completely new horizons for protein design and development.

Dr. NSc.

Dr. NSc.Eng. Luciano Pighinelli

Head of Computational Chemistry at Biomatter | Creating proteins with Intelligent Architecture™

Masoud Kazemi

Chief Scientific Officer at Biomatter

Linas Zakrys

Principal at UVC Partners

Oliver Schoppe

Biomatter is heading to Sweden for #BioEurope2024 ! We're looking forward to connecting with industry leaders and exchanging the latest insights in the biotech field. Indrė will be there to explore how Biomatter can support streamlining enzyme-based processes or drive forward new product ideas. Make sure to reach out and find a time to meet her! #Biomatter #ProteinArchitects #IntelligentArchitecture #EnzymeDevelopment #EnzymeOptimization #EnzymeEngineering

Throwback to last week… and WOW 🤩 #InvestorCamp and #StartupFair had us absolutely buzzing. From panels, nonstop networking, startup pitches, and yes, gin-infused drinks — the energy was OFF THE CHARTS. 💥 Here’s the tea: ✨ Investor Camp: Donatas Keras sat down with Juozas Nainys and Laurynas Karpus to talk life sciences + AI (and blew our minds) x Atrandi Biosciences x Biomatter ✨ Practica’s Aperitif? Drinks + vibes on point. ✨ Investor Camp Dinner - conversations flowing, connections made. ✨ Next day = all about startups. Arvydas Bloze hit the stage with Justinas Baranovskis to share the deets on their fresh Series B round x Ovoko \ RRR.LT ✨ Wrapped up with the ultimate Founders & Funders party — over 100 guests, co-hosted with FIRSTPICK , Earlybird Digital East Fund, and Northzone . Unreal. 📷 Here are some moments we've made together: https://lnkd.in/gm3WttVN Huge shoutout to all our friends & partners Lithuanian Private Equity and Venture Capital Association , Startup Lithuania , Lithuanian Business Angel Network LitBAN , and every single person we met. ❤️ Catch you at the next one.

Practica Capital

Exciting news from the world of computational protein engineering! The 2024 Nobel Prize in Chemistry has been awarded to David Baker, Demis Hassabis, and John M. Jumper for their pioneering contributions to protein design and structure prediction. Their work is transforming how we understand and manipulate proteins, creating entirely new possibilities in medicine, materials science, and beyond. 🚀 We couldn't be more inspired by this achievement, which points to a future where biology is reshaped by engineering proteins, including enzymes, playing a crucial role across industries - from pharmaceuticals and chemical manufacturing to food or life sciences. We're excited to be a part of this computational protein engineering journey, pushing the boundaries of enzyme development whilst creating a more sustainable and healthier world.

Let's meet in Milan this week. Drop me a message if you're attending the conference! 🔬🛸 #CPHI2024 #CPHI #Biomatter #EnzymeEngineering #IntelligentArchitecture

Ieva Lingytė

Biomatter team is heading to London this week! 🇬🇧 We're excited to dive into how protein-powered technologies are shaping a more sustainable, efficient food system while also driving innovation in novel food ingredients space. Our team members, Matthew and Ieva , are eager to connect and discuss how our Intelligent Architecture can help tackle enzyme-related challenges in the food industry. Let's connect and have a chat! #FutureFoodTech #EnzymeEngineering #IntelligentArchitecture #EnzymeDesign #Biomatter #ProteinArchitects

Get Ready for Investor Camp Next Week! 🚀 We’re excited to introduce one of the panels: The Intersection of Life Sciences and AI — a deep dive into one of the most groundbreaking and transformative fields today. This is your opportunity to hear directly from visionary founders who are shaping the future of healthcare, biotechnology, and artificial intelligence. Discover how these industries are converging to fuel game-changing innovations. 🔥 Meet the Panelists: Juozas Nainys , Co-Founder & CEO at Atrandi Biosciences Laurynas Karpus , Co-Founder & CEO at Biomatter The discussion will be moderated by our partner, Donatas Keras . 👉 Get your ticket: https://lnkd.in/dvyHuiiP P.S. As the event comes to a close, we'll invite all attendees for a pre-dinner networking gathering in a relaxed, informal setting - Aperitif by Practica. Looking forward to seeing you there! 👋

📣 Biomatter raises a €6.5 million round to unlock the power of generative AI for enzyme design 🎉 At Biomatter, we believe that the limitless potential to design new enzymes will contribute to building a better future for everyone. The new funding brings us one step closer to realizing our vision. We are excited to announce the new €6.5 million financing round to further expand the unique capabilities of our platform and create new-to-world enzymes. This achievement would not have been possible without the incredible dedication of the entire Protein Architects team at Biomatter , who consistently go above and beyond to reimagine what's possible with enzymes. The investment round was led by Inventure and UVC Partners , joined by existing investors Practica Capital and Metaplanet , as well as esteemed business angels and industry experts. For more insights, check out the article from SynBioBeta in the comments. #Biomatter #ProteinaArchitects #EnzymeDevelopment

After an incredible week at #GRC Biocatalysis 2024, I wanted to take a few days to gather my thoughts and capture learnings from what is one of my favourite conferences in the calendar. It was a pleasure to be able to present what Biomatter is doing on the stage next to established folks like Stefan Lutz, who did an excellent intro to mRNA on my behalf as well as the other industry folks- Martin Hayes , Kai Baldenius , Hans Iding , Richard Fox and Lara Zetzsche . As Biomatter looks to change the way we think about engineering enzymes it was exciting to share tangible examples of processes developed from our tech, all whilst having some of the best minds in this space meet me with enthusiasm and curiosity. All thanks of course to Sabine Flitsch and Carlos for the invite to speak and for organising a marvellous event. Looking forward to the next edition with Mélanie Hall , Radka Snajdrova already with of course my congratulations to my friends Scott France and Dörthe for being elected to run the show in 2028! So- what did I take away that maybe some in my network want to get their brains ticking over. 1) mRNA is here to stay, and we need tools and raw materials to meet the future demand. >30 tonnes of RNA materials expected to be needed to meet 2030 demand. Fortunately this is something Biomatter has been ahead of the curve on for a while and we will continue to lead the way 2) Pharma is continuing to focus on PMI, but at the same time we are still seeing glucose used as the default hydride source. Maybe it’s time to change that. There’s some obvious reasons we still rely on GDH, what innovations could replace this workhorse? 3) Folks are very excited about the rate of change in the enzyme ML/AI space for accessing new enzymes. With new models coming out so regularly, how are we keeping on top of what the best in class for both academic and industry use. One major challenge remains the accuracy of a lot of the current models in predicting functional enzymes. While some folks are pushing hard down the “more data” to train on track, others are continuing to show that blending physics with AI gives the best performance in terms of speed and accuracy. A bonus thought, the complexity of reactions we are able to unlock is increasing all the time, from modified nucleosides ( Sarah Lovelock ) to controlled radical mechanisms,( Yang Yang ). Echoing the thoughts of Jared Lewis as to what the next “do it all platform” enzyme will look like. What the most needed reaction we cannot yet do reliably with enzymes? Lastly, the GRC is not just about the latest and greatest science, there’s always old and new friends and catch up with. A pleasure as always ( Rachel Heath , Christian Schnepel , Nicholas Turner , John Woodley , Bethany Hogg Bo Couture , and Bettina Nestl amongst others I have surely forgotten along with the networking rockstar that is Johanna Thompson (fd Löfgren) Already looking forward to the next edition.

Matthew Thompson

Biomatter is back on the road! 🚀 Next week, don't miss our VP - Programs, Matthew Thompson , at the Gordon Research Conference - Biocatalysis, where he will showcase how Intelligent Architecture™ enables production from novel and improved synthetic routes to target molecules through novel reaction steps. Catch Matthew at the conference to dive deeper into our novel enzyme engineering approach! #GordonResearchConference2024 #Biocatalysis #ProteinArchitects #EnzymeDesign #EnzymeDiscovery #EnzymeEngineering #LYNXEnzymeOptimization

Make sure to catch Indrė Surgelytė and explore how Biomatter is reshaping biology! 🔎

Metric
Company Name	Biomatter	Mammoth Biosciences	Amyris, Inc.	Atomwise
Symbol			AMRS
MSH ID	COM:BIOMATTER	BIO:MAMMOTH	COM:AMYRIS	COM:ATOMWISE
Market	PRIVATE	PRIVATE	STOCKS	PRIVATE
Sector	Technology	Healthcare & Health Services	Basic Materials	Healthcare
Industry	Biotechnology	Biotechnology	Chemicals - Specialty	Pharmaceuticals
Country	LT	US	US	US
Stage		Series D
Employee Count		185	1.60K	73
Website	biomatter.com	mammoth.bio	amyris.com	atomwise.com
LinkedIn	biomatter	mammothbio		atomwise
Founders

Metric
Market Cap		18.47M
Enterprise Value
Monthly Web Traffic	6.85K
Web Traffic Growth	-0.30
Valuation
Raised Capital	150M

Metric
Revenue			269.85M
Revenue (LTM)
Revenue (NTM)
Gross Profit			11.18M
EBITDA			-514.21M
Operating Income			-592.66M
Net Income			-535.93M
EPS			-1.67
Diluted EPS			-1.58
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			-0.01
Operating Profit Margin			-2.06
EBITDA Margin			-1.91
Net Profit Margin			-2.56
Return on Equity			0.99
Return on Assets			-0.76
Return on Capital Employed			-2.00

BIOM

COM:BIOMATTER

Biomatter

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			-0.03
P/B Ratio			-0.03
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			0.09
EV Multiple			2.39

Metric
Days Sales Outstanding			125.86
Days Payables Outstanding			280.05
Days Inventory Outstanding			194.28
Operating Cycle			360.57
Cash Conversion Cycle			4.04
Asset Turnover			0.30

Metric
Operating Cash Flow			-525.89M
Free Cash Flow			-631.84M
Cash Flow to Debt			-0.31
Operating Cash Flow/Sales			-1.56
Free Cash Flow Yield			-29.26

Metric
Cash & Equivalents			64.44M
Accounts Receivable			-9.58M
Inventory			111.88M
Goodwill			142.57M
Debt to Capitalization			2.80
Debt to Assets			1.52
Current Ratio			0.52
Quick Ratio			0.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.16
R&D to Revenue			0.41
SG&A to Revenue